Press release

WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England

News WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England Published date: 18/09/2020 AKCUK-076 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available…

Read More

Akcea response to draft negative guidance from NICE for WAYLIVRA▼® (volanesorsen), the only therapy for FCS, a devastating and ultra-rare disease

News Akcea response to draft negative guidance from NICE for WAYLIVRA▼® (volanesorsen), the only therapy for FCS, a devastating and ultra-rare disease Published date: 02/01/2020 AKCUK-070 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on…

Read More

NICE issues final guidance for Tegsedi®▼ (inotersen) for hATTR amyloidosis

News NICE issues final guidance for Tegsedi®▼ (inotersen) for hATTR amyloidosis Published date: 23/05/2019 AKCUK-072 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England Akcea response to draft negative guidance from…

Read More

Akcea and Ionis Announce Authorisation of WAYLIVRA▼® (volanesorsen) in the European Union

News Akcea and Ionis Announce Authorisation of WAYLIVRA▼® (volanesorsen) in the European Union Published date: 08/05/2019 AKCUK-074 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England Akcea response to draft negative…

Read More

Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRA™▼ (volanesorsen)

News Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRA™▼ (volanesorsen) Published date: 01/03/2019 AKCUK-073 | September 2020 View Fullscreen Back to news listing Recent Posts WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England Akcea response to draft negative guidance…

Read More